Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

CancerMultiOm

Financiado

Deciphering Cancer Heterogeneity and Drug resistance using Single-Clone Genomic...

Deciphering Cancer Heterogeneity and Drug resistance using Single-Clone Genomic and Epigenomic Landscapes To comprehend the characteristics, phylogenetic relationships, and drug resistance of tumor subclones, measurements must be performed at single-cell or single-clone resolution. Aims 1 and 2 aim to create cost-effective and reliabl... ver más

30/11/2028

THE HEBREW UNIVERS...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

THE HEBREW UNIVERSITY OF JERUSALEM No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-11-28

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2023-COG: ERC CONSOLIDATOR GRANTS

I+D

Cerrada hace 1 año

0% 100%

1 Participantes

THE HEBREW UNIVERSITY OF JER...

2.00M€ | Lider

Proyectos interesantes

MultiCloneSeq Single-Clone Multi-omics Sequencing for Cancer Diagnosis 150K€ Cerrado

RTI2018-102204-B-I00 MECANISMOS DE RESISTENCIA A TERAPIAS ANTITUMORALES 375K€ Cerrado

CancerFLCloneSeq Clone-based full-length RNA-seq for early diagnosis of cance... 150K€ Cerrado

EQC2018-005144-P Plataforma de genómica para secuenciación de célula única y... 168K€ Cerrado

CRISPRCINIMM Revealing genes that mediate the CIN-induced interferon-infl... 188K€ Cerrado

SAF2017-89109-P ATLAS DE CELULA UNICA SOBRE LA HETEROGENEIDAD CELULAR CON RE... 218K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 60 meses Fecha Inicio: 2023-11-28
Fecha Fin: 2028-11-30

Líder del proyecto

THE HEBREW UNIVERSITY OF JERUSALEM

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto To comprehend the characteristics, phylogenetic relationships, and drug resistance of tumor subclones, measurements must be performed at single-cell or single-clone resolution. Aims 1 and 2 aim to create cost-effective and reliable single-cell drop technologies for capturing full-length RNA (Scfl-RNA-Seq) and enhancers at the DNA level (ChromOpen). It is noteworthy that Scfl-RNA-Seq also captures non-coding and non-polyadenylated RNAs besides coding mRNA. ChromOpen also offers better capturing of functional enhancers and higher sensitivity compared to the conventional technology. The ultimate goal of Aim 3 is to create the first technology that can capture both full-length RNA and enhancers from the same cell (Multi-Omics). To increase sensitivity and coverage, Multi-Omics will be combined with a 3D-culturing system (3Dclone) that facilitates growth of primary cancer cells into small clones. The single-clone based Multi-Omics maps will increase the discovery rate of genetic somatic diversity, including non-coding regions, reveal connections between gene expression and mutated loci, and display a wider range of functional state associations between cells. In Aim 4, using our innovative mapping technologies, we will investigate two brain tumors: Non-Small Cell Lung Cancer that has spread to the brain and Glioblastoma primary cells. Both of these cancers have limited treatment options and poor outcomes due to drug resistance. Based on temporal drug treatment experiments and advanced mapping technologies, this data will improve our understanding of somatic driver mutations and cellular diversity in the context of resistance, and ultimately, lead to the identification of new therapeutic targets.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores